News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Richard De Boer

Articles by Richard De Boer

28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

ByKevin Kalinsky, MD, MS,Erika P. Hamilton, MD,Laura Spring,Peter A. Fasching,Sandra Franco, MD,Richard De Boer,Javier Cortes,Dejan Juric,Aditya Bardia, MD, MPH, FASCO,Sina Haftchenary,Agnes Lteif,Juan Pablo Zarate,Liyi Cen,Patrick Neven, MD, PhD

April 27th 2023

50 Pooled Exploratory Analysis of Survival in Patients (pts) With HR+/ HER2− Advanced Breast Cancer (ABC) and Visceral Metastases (mets) Treated With Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Trials

ByDenise A. Yardley, MD,Yoon Sim Yap,Hamdy Abdel Azim,Richard De Boer,Mario Campone,Alistair Ring,Michelino De Laurentiis,Joyce A. O’Shaughnessy,Javier Cortes,Yogesh Chattar,Astrid Thuerigen,Juan Pablo Zarate,Liz Santarsiero

April 27th 2023

Latest Updated Articles

Trending on CancerNetwork

Emerging Strategies in Prostate Cancer: Molecular Glues and T-Cell Engagers

BCMA-Directed Bispecific Antibodies Navigating a New Era in Relapsed/Refractory Multiple Myeloma

What’s The State of Immunotherapy, Transplantation in Hematologic Oncology?

NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium

Novel Immunotherapy Reduces Breast Recurrence Rates in Non-HLA-A*02 Population